Moonlake Immunotherapeutics

MoonLake Immunotherapeutics has launched a public offering of 9 million shares and 1 million pre-funded warrants to raise approximately $200 million.

MoonLake Immunotherapeutics shareholders approved an amendment to the 2022 Equity Incentive Plan, increasing share availability and modifying vesting and other terms.

MoonLake Immunotherapeutics has entered into a Master Commercial Supply Agreement with Vetter Pharma International GmbH for the manufacturing of its product candidates.

MoonLake Immunotherapeutics announced a positive final pre-BLA meeting with the FDA for sonelokimab in hidradenitis suppurativa, aligning on submission plans and label strategy, and reported Q1 2026 financial results.

MoonLake Immunotherapeutics announced positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, secured an amended $500 million debt facility with Hercules Capital, and reported 2025 financial results.

MoonLake Immunotherapeutics received positive FDA feedback, confirming a pathway for Sonelokimab's Biologic License Application in Hidradenitis Suppurativa without additional clinical trials.

MoonLake Immunotherapeutics reports increased R&D spending and net loss in Q1 2026, driven by clinical trial progression and stock option expense, while maintaining sufficient capital through 2027.

MoonLake Immunotherapeutics reported increased losses and mixed Phase 3 hidradenitis suppurativa trial results, impacting its debt facility, while advancing other clinical programs.

MoonLake Immunotherapeutics reports increased R&D expenses and net losses in Q2 2025, driven by advanced clinical trials, while securing significant debt financing to extend its cash runway into 2028.

MoonLake Immunotherapeutics reports a net loss of $40.6 million for Q1 2025, alongside updates on its clinical development programs and a new $500 million loan facility.

MoonLake Immunotherapeutics reported a net loss of $36.1 million for the third quarter of 2024, with significant increases in research and development expenses as the company advances its clinical programs.

MoonLake Immunotherapeutics reports increased R&D spending and a net loss for Q2 2024, while highlighting progress in clinical trials for Sonelokimab.

MoonLake Immunotherapeutics' 2025 annual report details significant clinical progress for Sonelokimab across multiple inflammatory diseases, despite increased net losses.

MoonLake Immunotherapeutics' 10-K filing details the company's financial results for 2024 and provides an update on the clinical development of their lead asset, Sonelokimab (SLK), across multiple inflammatory disease indications.

MoonLake Immunotherapeutics has filed an amendment to its annual report on Form 10-K, correcting a minor error in certifications and reaffirming the accuracy of its financial statements and internal controls.

MoonLake Immunotherapeutics' 10-K filing highlights positive clinical trial results for Sonelokimab (SLK) and provides an overview of the company's financial status and future plans.

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 1,100 shares of common stock on July 27, 2026 for $20.00 per share.

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 52,448 shares of common stock on July 21, 2026.

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 43,700 shares of common stock on July 20, 2026 for $20.09 per share.

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 16,105 shares of common stock on July 15, 2026 for $20.01 per share.

Da Silva Jorge Santos, Chief Executive Officer and a Director of MoonLake Immunotherapeutics, sold 102,225 shares of common stock on July 9, 2026.

MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 47,775 shares of Class A ordinary shares for approximately $20.03 per share, executed under a pre-arranged trading plan.

MoonLake Immunotherapeutics has issued its 2026 proxy statement detailing director elections, auditor ratification, and a proposed 5 million share increase to its equity incentive plan.

MoonLake Immunotherapeutics announces its 2024 Annual General Meeting of Shareholders to be held on June 5, 2024, with voting open until June 4, 2024.

MoonLake Immunotherapeutics has released its proxy statement for the 2025 Annual General Meeting of Shareholders, scheduled for June 5, 2025, covering director elections, auditor ratification, and executive compensation.

MoonLake Immunotherapeutics announces its 2024 Annual General Meeting of Shareholders to be held on June 5, 2024, with voting open until June 4, 2024.

MoonLake Immunotherapeutics will hold its 2024 Annual General Meeting on June 5, 2024, to vote on director elections, auditor ratification, executive compensation, and the frequency of future executive compensation votes.

BVF entities have increased their beneficial ownership in MoonLake Immunotherapeutics to 19.7% following a recent share offering.

BVF entities report beneficial ownership of 22.3% of MoonLake Immunotherapeutics' Class A ordinary shares following recent transactions.

BVF Partners and affiliates report a revised 27.7% beneficial ownership in MoonLake Immunotherapeutics following an increase in outstanding shares.

Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 6.25% in MoonLake Immunotherapeutics' Class A ordinary shares.

Cormorant Asset Management, LP and Bihua Chen have reported a 6.10% beneficial ownership stake in MoonLake Immunotherapeutics' Class A ordinary shares.

Avoro Capital Advisors LLC and Behzad Aghazadeh reported a 3.15% beneficial ownership stake in MoonLake Immunotherapeutics' Class A Ordinary Shares.

Deep Track Capital and affiliates have disclosed a passive beneficial ownership of 6.46% in MoonLake Immunotherapeutics' Class A ordinary shares.

FMR LLC and Abigail P. Johnson have filed an Amendment No. 4 to their Schedule 13G, reporting a 1.1% beneficial ownership in Moonlake Immunotherapeutics' Class A Common Stock as of September 30, 2025.

Bihua Chen, general partner of Cormorant Asset Management, LP, reported a 3.14% beneficial ownership stake in MoonLake Immunotherapeutics' Class A Ordinary Shares.